Cara Therapeutics, Inc. (CARA) will report its next earnings on Aug 07 AMC. The company reported the earnings of $-0.52/Share in the last quarter where the estimated EPS by analysts was $-0.32/share. The difference between the expected and actual EPS was $-0.2/share, which represents an Earnings surprise of -62.5%.
Many analysts are providing their Estimated Earnings analysis for Cara Therapeutics, Inc. and for the current quarter 7 analysts have projected that the stock could give an Average Earnings estimate of $-0.5/share. These analysts have also projected a Low Estimate of $-0.61/share and a High Estimate of $-0.4/share.
Some buy side analysts are also providing their Analysis on Cara Therapeutics, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Cara Therapeutics, Inc. might touch $28 high while the Average Price Target and Low price Target is $26.43 and $24 respectively.
The Relative Volume of the company is 1.21 and Average Volume (3 months) is 985.55 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -56.9%. The Return on Equity (ROE) value stands at -73.2%. While it’s Return on Investment (ROI) value is -37.7%.
While looking at the Stock’s Performance, Cara Therapeutics, Inc. currently shows a Weekly Performance of 8.01%, where Monthly Performance is 16.4%, Quarterly performance is 27.92%, 6 Months performance is 61.14% and yearly performance percentage is 62.06%. Year to Date performance value (YTD perf) value is 75.16%. The Stock currently has a Weekly Volatility of 3.41% and Monthly Volatility of 3.33%.